Deepak Rohila*

Department of Pathology, Uniformed Services University of the Health Sciences and Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, USA

*Corresponding Author: Deepak Rohila, Department of Pathology, Uniformed Services University of the Health Sciences and Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, USA.

Received: February 27, 2023; Published: March 27, 2023

Abstract

CAR-T therapy, or chimeric antigen receptor T-cell therapy, has shown remarkable success in treating certain blood cancers, such as leukemia and lymphoma. However, the use of CAR-T therapy for solid tumors has been more challenging. Solid tumors are complex and heterogeneous, making it difficult to identify specific antigens that can be targeted by CAR-T cells. In addition, solid tumors often have a hostile microenvironment that can inhibit CAR-T cell function and survival.

References

1. Hegde M., et al. “Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape”. Journal of Clinical Investigation8 (2016): 3036-3052.
2. Newick K., et al. “CAR T Cell Therapy for Solid Tumors”. Annual Review of Medicine 68 (2017): 139-152.
3. Drent E., et al. “Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma”. Haematologica5 (2016): 616-625.
4. Liu X., et al. “A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors”. Cancer Research6 (2016): 1578-1590.
5. Zhang E., et al. “Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors”. Molecular Cancer 17 (2018): 7.

Citation

Citation: Deepak Rohila. “CAR-T Therapy for Solid Cancer: Challenges and Solutions" Acta Scientific Cancer Biology 7.2 (2023): 03-04.

Copyright

Copyright: © 2023 Deepak Rohila. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.